Table 1.
Subject characteristics
| |
Without NAFLD |
With NAFLD |
||||
|---|---|---|---|---|---|---|
| Variables |
Total |
Non-CAD |
CAD |
Total |
Non-CAD |
CAD |
| N = 183 | N = 47 | N = 136 | N = 70 | N = 27 | N = 43 | |
| Sex(Male/Female) |
121/62 |
23/24 |
98/38 |
43/27 |
16/11 |
27/16 |
| Age, years |
67.2 ± 10.0 |
64.6 ± 9.9 |
68.2 ± 9.9* |
63.9 ± 9.9# |
61.3 ± 7.7 |
65.5 ± 10.9 |
| Body mass index, kg/m2 |
23.9 ± 3.1 |
24.0 ± 3.5 |
23.9 ± 2.9 |
26.5 ± 3.7## |
26.5 ± 4.9 |
26.5 ± 2.8 |
| Waist circumference, cm |
88.4 ± 9.3 |
86.7 ± 9.8 |
88.9 ± 9.0 |
95.4 ± 9.3## |
96.6 ± 11.7 |
94.7 ± 7.6 |
| Systolic blood pressure, mmHg |
130.0 |
130.0 |
130.0 |
140.0 |
140.0 |
140.0 |
| (120.0-148.0) |
(119.0-150.0) |
(120.0-147.8) |
(128.8-151.5)# |
(120.0-150.0) |
(130.0-153.0) |
|
| Diastolic blood pressure, mmHg |
80.0 |
80.0 |
80.0 |
80.0 |
80.0 |
80.0 |
| |
(70.0-80.0) |
(70.0-85.0) |
(70.0-80.0) |
(71.8-90.0)## |
(70.0-85.0) |
(72.0-90.0) |
| Fasting plasma glucose, mmol/L |
5.3(4.9-6.1) |
5.3(5.0-5.9) |
5.3(4.9-6.1) |
5.8(5.2-7.2)## |
5.6(5.1-6.6) |
5.9(5.4-7.7) |
| 2 h postprandial glucose, mmol/L |
7.9(6.4-10.7) |
7.5(6.1-9.3) |
8.0(6.5-11.5)* |
10.4(8.2-12.9)## |
9.7(7.9-12.9) |
11.3(8.2-12.9) |
| HbA1c,% |
6.1(5.7-6.5) |
5.9(5.6-6.3) |
6.2(5.8-6.6) |
6.5(5.9-7.6)## |
6.3(5.7-7.1) |
6.6(6.2-7.9) |
| HOMA-IR |
3.8(2.4-5.3) |
3.7(2.4-5.4) |
3.9(2.4-5.3) |
6.0(3.7-7.2)## |
5.9(3.7-6.4) |
6.6(3.7-9.2) |
| Total cholesterol, mmol/L |
4.3 ± 1.0 |
4.6 ± 1.1 |
4.2 ± 1.0* |
4.7 ± 1.3# |
4.5 ± 1.4 |
4.8 ± 1.2 |
| Triglyceride, mmol/L |
1.4(1.0-1.9) |
1.4(0.9-2.0) |
1.4(1.0-1.8) |
2.2(1.4-3.1)## |
1.7(1.3-2.4) |
2.6(1.6-3.7)* |
| HDL-c, mmol/L |
1.1 ± 0.3 |
1.2 ± 0.3 |
1.1 ± 0.3* |
1.0 ± 0.3## |
1.0 ± 0.3 |
1.0 ± 0.3 |
| LDL-c, mmol/L |
2.9 ± 1.0 |
3.0 ± 0.9 |
2.9 ± 1.0 |
3.1 ± 1.0 |
3.1 ± 1.0 |
3.2 ± 1.0 |
| C-reactive protein, mg/L |
1.2(0.5-3.1) |
1.0(0.4-3.0) |
1.2(0.5-3.3) |
2.3(1.0-6.9)## |
1.6(0.7-6.3) |
2.5(1.1-7.6) |
| FGF21, pg/mL |
273.3 |
256.1 |
277.8 |
388.0 |
321.5 |
415.5 |
| (164.9-383.7) |
(150.6-351.9) |
(171.1-406.6)* |
(253.0-655.4)## |
(239.1-497.6) |
(258.0-693.7)* |
|
| Smoker n (%) |
82(44.8) |
16(34.0) |
66(48.5) |
31(44.3) |
12(44.4) |
19(44.2) |
| Metabolic syndrome and its components | ||||||
| Abdominal obesity n (%) |
93(50.8) |
22(46.8) |
71(52.2) |
55(78.6)## |
21(77.8) |
34(79.1) |
| Hypertriglyceridemia n (%) |
87(47.5) |
20(42.6) |
67(49.3) |
50(71.4)## |
14(51.9) |
36(83.7)** |
| Low HDL-c n (%) |
73(39.9) |
15(31.9) |
58(42.6) |
41(58.6)# |
14(51.9) |
27(62.8) |
| Hypertension n (%) |
160(87.4) |
41(87.2) |
119(87.5) |
63(90.0) |
23(85.2) |
40(93.0) |
| Hyperglycemia n (%) |
105(57.4) |
25(53.2) |
80(58.8) |
56(80.0)## |
21(77.8) |
35(81.4) |
| Metabolic syndrome n (%) |
105(57.4) |
24(51.1) |
81(59.6) |
63(90.0)## |
23(85.2) |
40(93.0) |
| Dyslipidemia n (%) | 142(77.6) | 34(72.3) | 108(79.4) | 68(97.1)## | 25(92.6) | 43(100.0) |
Data were expressed as mean ± SD or median (interquartile range). For both the non-NAFLD and NAFLD groups: *P < 0.05 CAD vs. non-CAD; **P < 0.01 CAD vs. non-CAD. For the total subjects with and without NAFLD: #P < 0.05 NAFLD vs. non-NAFLD; ##P < 0.01 NAFLD vs. non-NAFLD.